April 10, 2019 10:48 AM EDT

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

John Carroll

Editor & Founder

Can real-world evidence substitute for a clinical drug trial that meets the full gold standard on data?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access

FDA, Brigham and Women’s to test if RWE is ripe now for re­plac­ing clin­i­cal drug tri­als

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

In rare move, Colom­bia is­sues com­pul­so­ry li­cense for HIV med­i­cine in ef­fort to ex­pand ac­cess

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access